NR1H4 and gastric cancer: As a measure of clinical relevance, using a retrospective database analysis, the authors found that the use of bile acid sequestrants in humans was associated with reduced gastric cancer risk, and expression of a bile acid receptor, TGR5, paralleled disease severity.